Bevacizumab-associated mesenchymal expansion in paediatric high-grade glioma is accompanied by intercellular VEGFA – AXL coupling
This study reanalyzes a longitudinal paediatric high-grade glioma single-nucleus atlas to reveal that bevacizumab treatment drives a specific mesenchymal expansion coupled with myeloid polarization through a non-canonical, hypoxia-independent intercellular VEGFA–AXL axis mediated by bevacizumab-sparing NRP1 receptors.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Cancer is often thought of as a single, uniform enemy, but inside a tumour, cells are constantly changing their identities. Some cells act like the tissue they came from, while others transform into a more aggressive, scar-like form known as a mesenchymal state. This shift is dangerous because it often makes the cancer harder to treat. Doctors have long used a drug called bevacizumab to starve tumours of their blood supply, hoping to stop them from growing. The drug works by blocking a specific protein that tells blood vessels to grow. However, in many patients, the tumour eventually returns, and scientists have suspected that the cancer cells might be adapting to the lack of blood by switching into this tougher, scar-like state. The question has remained: does this switch actually happen in children with aggressive brain tumours, and if so, what triggers it?
A new study by Virginia Savova takes a deep dive into this mystery by examining the genetic blueprints of thousands of individual cells from children with high-grade glioma, a severe type of brain cancer. The researchers looked at samples taken from patients at different times: when they were first diagnosed, when the cancer came back, and in some cases, after the patients had passed away. By comparing these snapshots over time, they could see how the tumour cells changed as the patients received different treatments. The study focused specifically on patients who had received bevacizumab, sometimes combined with another type of therapy that boosts the immune system, to see if the drug was driving the cancer cells to change their nature.
The analysis revealed a clear pattern that had been missed in previous, broader studies. When the researchers looked closely at the specific types of cells present, they found that the aggressive, scar-like state did not simply appear randomly. Instead, it expanded significantly in patients who received bevacizumab. In fact, the more of this drug a patient received, the more the tumour shifted toward this resistant state. The effect was most dramatic in patients who received bevacizumab along with immune-boosting drugs, where the proportion of these tough cells jumped from a small fraction to nearly forty percent of the tumour. In contrast, patients who did not receive bevacizumab saw this aggressive cell type shrink or stay the same. This suggests that the treatment intended to starve the tumour may be inadvertently encouraging the most dangerous cells to take over.
To understand how this happens, the researchers mapped the journey of the cancer cells. They discovered that the tumour does not jump straight from a normal state to the aggressive one. Instead, there is a specific intermediate step, a distinct type of cell that acts as a bridge. This bridge cell sits right next to the aggressive state in the tumour's genetic landscape. The study found that this bridge cell is the one that is being consumed or transformed into the aggressive form as the treatment continues. It is as if the treatment is pushing the cells through a specific doorway that leads directly to the most resistant version of the cancer.
The story does not end with the cancer cells alone. The study also looked at the immune cells living inside the tumour, specifically the macrophages, which are a type of white blood cell that usually helps fight infection. In patients treated with bevacizumab, these immune cells changed their identity, shifting from a resident brain cell type to a form that is typically recruited from the bone marrow. Crucially, the researchers found a tight link between the number of these new immune cells and the amount of aggressive cancer cells. Where there were more of the bone-marrow-derived immune cells, there were more of the aggressive cancer cells.
The researchers then investigated how these two groups of cells might be talking to each other. They found a striking connection involving two specific proteins: one produced by the immune cells and another found on the surface of the cancer cells. The immune cells were sending out a signal protein, while the cancer cells were displaying a matching receptor to catch it. This connection was so strong that it appeared almost perfectly synchronized across the different patients. However, the researchers ruled out the most obvious way this communication usually happens. The standard receptors that typically catch this signal were almost completely absent from the cells. Instead, the cancer cells were using a different, less common receptor that the drug bevacizumab does not block. This means the cancer cells found a backdoor to receive the signal they needed to survive and grow, bypassing the drug's intended blockade.
The study also looked at other potential signals that might be driving this change, such as other proteins known to recruit immune cells. While some of these signals were present, the researchers could not separate their effects from the immune-boosting drugs, leaving their exact role unclear. What remains clear is that the drug bevacizumab is associated with a specific chain of events: it encourages a shift in the immune cells, which in turn seems to support the growth of a specific, highly resistant type of cancer cell. The researchers did not find evidence that the drug works through the usual pathways or that other common signals are the primary drivers.
This work provides a detailed map of how a brain tumour in a child can adapt to treatment. It shows that the cancer is not a static mass but a dynamic system where cells change their roles in response to pressure. The findings suggest that the current treatment strategy might be selecting for the very cells it is trying to kill, by creating an environment where they thrive. The researchers point out that the protein the cancer cells use to receive the signal is a promising target for new drugs, as it is the key to this survival mechanism. However, they also caution that the data comes from a small number of patients and that the relationship between the immune cells and the cancer cells is complex. The study does not offer a new cure, but it offers a clearer view of the problem, showing exactly where the cancer cells are hiding and how they are communicating with their surroundings to survive.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.